findmyKOL

Alan Parsa, MD

Basic profile

University of Hawaiʻi at Mānoa

ORCIDNone on fileNPI
RegionHonolulu, HI · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Alan Parsa is an Endocrinology/Metabolic physician affiliated with University of Hawaiʻi at Mānoa. OpenAlex indexes 67 publications with 1,959 citations (h-index 20).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
67publications

Distinct works indexed by OpenAlex.

1,959citations

Total citations across indexed works.

20h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
58companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

58 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

58 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    69.3%
    GLP-1 receptor agonist22.6%
    Ozempic51%Trulicity31%Rybelsus9%Mounjaro5%Victoza 3-Pak5%
    Part D<11 patients
    Insulin Analog15.8%
    Lantus Solostar25%Tresiba Flextouch U-10020%Novolog Flexpen19%Humalog Kwikpen U-10016%Toujeo Max Solostar9%Basaglar Kwikpen U-1008%Tresiba Flextouch U-2005%
    Part D<11 patients

    + 9 more classes in this area

  • Hormonal (systemic)

    17.3%
    l-Thyroxine11.6%
    Levothyroxine Sodium90%Synthroid10%
    Part D109 patients
    Thyroid Hormone Synthesis Inhibitor2.9%
    Methimazole100%
    Part D37 patients

    + 3 more classes in this area

  • Cardiovascular

    6.2%
    Statin1.9%
    Atorvastatin Calcium55%Simvastatin25%Rosuvastatin Calcium20%
    Part D<11 patients
    Nonsteroidal Mineralocorticoid-Receptor Antagonist1.7%
    Kerendia100%
    Part D13 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”